Abstract
Plain Language SummaryPatients with chronic kidney disease (CKD) can develop high potassium (hyperkalemia) levels in their blood that can lead to complications such as heart issues. Renin-angiotensin-aldosterone system inhibitors (RAASis) are used as treatment for heart failure and CKD, but can also cause hyperkalemia, so are underutilized and used at lower than optimal doses. Patiromer is a potassium binder which was investigated in the DIAMOND trial to identify if it could reduce hyperkalemia in patients receiving RAASis. Lower kidney function (eGFR) has been associated with a greater likelihood of stopping treatment with RAASis; therefore, this analysis assessed the effect of patiromer on patients with varying eGFR levels. Patiromer enabled use of effective RAASi doses, controlled the serum potassium levels and minimized hyperkalemia in patients with heart failure and CKD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
